drugset / Trial / NCT05375994

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

NCT05375994

Phase 1/2 Completed 12 enrolled Verastem, Inc. Mirati Therapeutics Inc. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

Timeline

Start
2022-08-01
Primary completion
2026-06-15
Completion
2026-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule
Subject Avutometinib Small molecule